12:23 PM
Unknown
Status epilepticus (SE) is a common, life-threatening neurologic disorder. It is essentially an acute, prolonged epileptic crisis
Stroke (remote or acute)
Hypoxic injury
Tumor
Subarachnoid hemorrhage
Head trauma
Drugs (eg, cocaine, theophylline); isoniazid (INH) may cause seizures and is unique in having a specific antidote, pyridoxine (vitamin B-6)
Alcohol withdrawal
Electrolyte abnormalities (eg, hyponatremia, hypernatremia, hypercalcemia, hepatic encephalopathy)
Neoplasms
CNS infections (eg, meningitis, brain abscess, encephalitis)
Toxins, notably sympathomimetics
A comparison of initial IV treatment for overt generalized convulsive SE by Treiman et al found that lorazepam was more effective than phenytoin alone. Lorazepam was not more effective than phenobarbital or diazepam plus phenytoin, but it was easier to use. Not studied was fosphenytoin, which is theoretically a significant improvement over phenytoin.
Intravenous valproic acid has been shown in a pilot study to be equal to or better than phenytoin in aborting generalized SE, and it has been used in some cases of focal status epilepticus.
The use of levetiracetam (Keppra) in treatment of refractory SE has been examined, in part due to its availability in intravenous form, although its use in treating focal SE remains investigational. Anecdotal reports describe the beneficial use of topiramate in some cases of focal SE.
There are several intravenous formulations of antiepileptic drugs (AEDs) at different stages of development. Some of these might be able to help refractory cases with SE as adjunctive therapy.
No data clearly support a best third-line drug. Controlled trials are lacking, and recommendations vary greatly. While phenobarbital has historically been among the most widely used, the list of third-line drugs also includes midazolam, propofol, pentobarbital, valproate, levetiracetam, lidocaine, and others. Lacosamide, a novel antiepileptic drug available for intravenous injection, may be used safely as adjunctive therapy for SE, but little data exist on its efficacy.
A clinical practice trend seems to be for use of propofol as a third-line agent, often initiated during induction for endotracheal intubation. However, propofol infusion syndrome and increased mortality is reported when used at high doses and for prolonged periods.
=========================
JOIN OUR PAGE IN FACEBOOK
causes:
Stroke (remote or acute)
Hypoxic injury
Tumor
Subarachnoid hemorrhage
Head trauma
Drugs (eg, cocaine, theophylline); isoniazid (INH) may cause seizures and is unique in having a specific antidote, pyridoxine (vitamin B-6)
Alcohol withdrawal
Electrolyte abnormalities (eg, hyponatremia, hypernatremia, hypercalcemia, hepatic encephalopathy)
Neoplasms
CNS infections (eg, meningitis, brain abscess, encephalitis)
Toxins, notably sympathomimetics
Antiepileptic Drug:
Benzodiazepines are the preferred first-line agents. Although diazepam is familiar to paramedics and emergency physicians, a consensus has evolved among neurologists and epileptologists that lorazepam may be preferred in this setting because of its long distribution half-life.A comparison of initial IV treatment for overt generalized convulsive SE by Treiman et al found that lorazepam was more effective than phenytoin alone. Lorazepam was not more effective than phenobarbital or diazepam plus phenytoin, but it was easier to use. Not studied was fosphenytoin, which is theoretically a significant improvement over phenytoin.
Intravenous valproic acid has been shown in a pilot study to be equal to or better than phenytoin in aborting generalized SE, and it has been used in some cases of focal status epilepticus.
The use of levetiracetam (Keppra) in treatment of refractory SE has been examined, in part due to its availability in intravenous form, although its use in treating focal SE remains investigational. Anecdotal reports describe the beneficial use of topiramate in some cases of focal SE.
First Aid for Status Epilepticus
No data clearly support a best third-line drug. Controlled trials are lacking, and recommendations vary greatly. While phenobarbital has historically been among the most widely used, the list of third-line drugs also includes midazolam, propofol, pentobarbital, valproate, levetiracetam, lidocaine, and others. Lacosamide, a novel antiepileptic drug available for intravenous injection, may be used safely as adjunctive therapy for SE, but little data exist on its efficacy.
A clinical practice trend seems to be for use of propofol as a third-line agent, often initiated during induction for endotracheal intubation. However, propofol infusion syndrome and increased mortality is reported when used at high doses and for prolonged periods.
=========================
JOIN OUR PAGE IN FACEBOOK
Posted in: Medical,Neurology/Neurosurgery
0 comments:
Post a Comment